Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist

被引:158
作者
Cascio, M. G. [1 ]
Gauson, L. A. [1 ]
Stevenson, L. A. [1 ]
Ross, R. A. [1 ]
Pertwee, R. G. [1 ]
机构
[1] Univ Aberdeen, Sch Med Sci, Inst Med Sci, Aberdeen AB25 2ZD, Scotland
基金
美国国家卫生研究院;
关键词
cannabigerol; CP55940; mouse vas deferens; alpha(2)-adrenoceptor; 5-HT1A receptor; CB1; receptor; clonidine; dexmedetomidine; maprotiline; R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin; MOUSE VAS-DEFERENS; PHARMACOLOGICAL PROFILE; CB1; NORADRENALINE; HASHISH; RELEASE; DELTA(9)-TETRAHYDROCANNABIVARIN; ADRENOCEPTORS; CONSTITUENTS; CANNABIDIOL;
D O I
10.1111/j.1476-5381.2009.00515.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and purpose: Cannabis is the source of at least seventy phytocannabinoids. The pharmacology of most of these has been little investigated, three notable exceptions being Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. This investigation addressed the question of whether the little-studied phytocannabinoid, cannabigerol, can activate or block any G protein-coupled receptor. Experimental approach: The [S-35]GTP gamma S binding assay, performed with mouse brain membranes, was used to test the ability of cannabigerol to produce G protein-coupled receptor activation or blockade. Its ability to displace [H-3]CP55940 from mouse CB1 and human CB2 cannabinoid receptors and to inhibit electrically evoked contractions of the mouse isolated vas deferens was also investigated. Key results: In the brain membrane experiments, cannabigerol behaved as a potent alpha(2)-adrenoceptor agonist (EC50 = 0.2 nM) and antagonized the 5-HT1A receptor agonist, R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin (apparent K-B = 51.9 nM). At 10 mu M, it also behaved as a CB1 receptor competitive antagonist. Additionally, cannabigerol inhibited evoked contractions of the vas deferens in a manner that appeared to be alpha(2)-adrenoceptor-mediated (EC50 = 72.8 nM) and displayed significant affinity for mouse CB1 and human CB2 receptors. Conclusions and implications: This investigation has provided the first evidence that cannabigerol can activate alpha(2)-adrenoceptors, bind to cannabinoid CB1 and CB2 receptors and block CB1 and 5-HT1A receptors. It will now be important to investigate why cannabigerol produced signs of agonism more potently in the [S-35]GTP gamma S binding assay than in the vas deferens and also whether it can inhibit noradrenaline uptake in this isolated tissue and in the brain. British Journal of Pharmacology (2010) 159, 129-141; doi:10.1111/j.1476-5381.2009.00515.x; published online 4 December 2009
引用
收藏
页码:129 / 141
页数:13
相关论文
共 38 条
[21]   Evidence that (-)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferens [J].
Pertwee, RG ;
Thomas, A ;
Stevenson, LA ;
Maor, Y ;
Mechoulam, R .
NEUROPHARMACOLOGY, 2005, 48 (08) :1139-1146
[22]   PHARMACOLOGICAL CHARACTERIZATION OF 3 NOVEL CANNABINOID RECEPTOR AGONISTS IN THE MOUSE ISOLATED VAS-DEFERENS [J].
PERTWEE, RG ;
GRIFFIN, G ;
LAINTON, JAH ;
HUFFMAN, JW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 284 (03) :241-247
[23]   (-)-cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens [J].
Pertwee, RG ;
Ross, RA ;
Craib, SJ ;
Thomas, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 456 (1-3) :99-106
[24]   Agonist-antagonist characterization of 6'-cyanohex-2'-yne-Delta(8)-tetrahydrocannabinol in two isolated tissue preparations [J].
Pertwee, RG ;
Fernando, SR ;
Griffin, G ;
Ryan, W ;
Razdan, RK ;
Compton, DR ;
Martin, BR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 315 (02) :195-201
[25]   Agonist inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630 [J].
Ross, RA ;
Brockie, HC ;
Stevenson, LA ;
Murphy, VL ;
Templeton, F ;
Makriyannis, A ;
Pertwee, RG .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (03) :665-672
[26]   Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens [J].
Ross, RA ;
Gibson, TM ;
Brockie, HC ;
Leslie, M ;
Pashmi, G ;
Craib, SJ ;
Di Marzo, V ;
Pertwee, RG .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (03) :631-640
[27]   Structural determinants of the partial agonist-inverse agonist properties of 6′-azidohex-2′-yne-Δ8-tetrahydrocannabinol at cannabinoid receptors [J].
Ross, RA ;
Gibson, TM ;
Stevenson, LA ;
Saha, B ;
Crocker, P ;
Razdan, RK ;
Pertwee, RG .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (03) :735-743
[28]   Stimulation frequency-noradrenaline release relationships examined in α2A-, α2B- and α2C-adrenoceptor-deficient mice [J].
Scheibner, J ;
Trendelenburg, NU ;
Hein, L ;
Starke, K .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 364 (04) :321-328
[29]   Modulation of transmitter release via presynaptic cannabinoid receptors [J].
Schlicker, E ;
Kathmann, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (11) :565-572
[30]   Presynaptic autoreceptors in the third decade:: focus on α2-adrenoceptors [J].
Starke, K .
JOURNAL OF NEUROCHEMISTRY, 2001, 78 (04) :685-693